Nectar Lifesciences reported a consolidated net loss of ₹2,928.85 crore for the financial year ended March 31, 2026 (FY26), a significant deterioration from the net loss of ₹1,136.81 crore in FY25. The financial performance was heavily impacted by the strategic divestment of its core pharmaceutical businesses and substantial losses on investment instruments.

The company's revenue from operations stood at nil for FY26, as it had disposed of its Active Pharmaceutical Ingredients (API) and formulation businesses through a slump sale to Ceph Lifesciences Private Limited. This transaction generated an exceptional gain of ₹1,633.73 crore, which was recognized under discontinued operations. However, this gain was more than offset by a pre-tax loss of ₹5,376.55 crore from discontinued operations and a pre-tax loss of ₹878.70 crore from continuing operations.

A critical drag on profitability was a ₹520.95 crore loss on investments, arising from volatility in capital markets affecting mutual fund instruments deployed by the company. Additionally, other income rose to ₹92.91 crore from ₹18.78 crore in the previous year, primarily driven by interest income of ₹70.40 crore.

Balance Sheet and Capital Structure

Nectar Lifesciences significantly deleveraged during the period, repaying all outstanding borrowings. Total borrowings dropped to nil from ₹5,820.23 crore in FY25. Consequently, the debt-to-equity ratio became non-applicable. Cash and cash equivalents increased substantially to ₹1,081.30 crore from ₹192.20 crore, bolstered by proceeds from the slump sale.

The company completed a buy-back of 3 crore equity shares at ₹27 per share, aggregating ₹810.00 crore, through the tender offer route in January 2026. Following the buyback, the paid-up equity share capital reduced to ₹194.26 crore. Promoter Mr. Sanjiv Goyal holds 24.63% of the equity, while Sanjiv (HUF) holds 22.46%.

Strategic Shift to Real Estate

Following the exit from pharmaceuticals, Nectar Lifesciences amended its object clause to include real estate activities. It acquired 100% of Avensis Exports Private Limited (AEPL) in March 2026, infusing an inter-corporate loan of ₹980.00 million into the subsidiary. The board is currently evaluating opportunities in residential, commercial, and industrial real estate sectors.

Board Appointments and Re-Appointments

The 31st Annual General Meeting (AGM), scheduled for September 18, 2026, will consider several board changes:

• Mr. Sanjiv Goyal: Re-appointment as Chairman & Managing Director, retiring by rotation.
• Dr. Kuldip Kumar Bhasin: Re-appointment as Independent Director for a second five-year term, despite having attained the age of 75 years, citing his expertise in scientific research.
• Dr. Indu Pal Kaur: Re-appointment as Independent Director for a second five-year term.
• Dr. Gunmala Suri: Appointment as Non-Executive Non-Independent Director, bringing over 27 years of experience in academic administration and research.

What the Numbers Show

The company’s financial profile has shifted from an operational manufacturing entity to a holding structure with significant cash reserves and no debt. The ₹520.95 crore investment loss constitutes approximately 17.4% of the total net loss, highlighting the risk associated with deploying surplus cash from asset monetization into volatile capital markets without immediate operational revenue generation. While the slump sale gain provided a one-time boost, the absence of revenue from operations means the company is currently reliant on interest income and potential real estate ventures for future earnings.

Nectar Lifesciences reported a consolidated net loss of ₹157.2 crore for the quarter ended June 30, 2026 (Q1FY27), marking a substantial improvement over the ₹632.3 crore loss posted in the corresponding quarter of FY26. The company’s revenue from continuing operations was ₹44.2 crore, a rise from ₹0.63 crore in Q1FY26.

The standalone entity also showed improved bottom-line figures, reporting a net loss of ₹134.6 crore compared to ₹632.3 crore in the prior year period. Both standalone and consolidated results include operations from discontinued segments, which contributed a net profit of ₹32.1 crore in Q1FY27, contrasting sharply with a ₹6,331.9 crore loss in Q1FY26.

Financial Performance Overview

The company’s financial data for Q1FY27 highlights a reduction in losses across both standalone and consolidated metrics. While revenue generation remains modest, the significant drop in losses suggests operational adjustments or one-time factors influencing the current period’s results compared to the heavy losses incurred previously.

What the Numbers Show

A key divergence exists between the pre-tax and after-tax positions when comparing current and prior periods. In Q1FY26, the consolidated entity reported a modest pre-tax profit of ₹13.5 crore, yet ended with a massive comprehensive loss of ₹6,323.1 crore. This indicates that non-operational items, likely related to discontinued operations or exceptional charges, drove the previous year’s deficit rather than core operational performance.

In Q1FY27, while the pre-tax loss widened to ₹2,462.0 crore, the total comprehensive loss narrowed to ₹1,539.8 crore. The discontinued operations segment contributed a net profit of ₹32.1 crore in the current quarter, whereas it had dragged down results with a ₹6,331.9 crore loss in Q1FY26. This shift underscores that the improvement in the overall loss figure is heavily influenced by the normalization or resolution of issues within the discontinued business units, rather than a reversal in the pre-tax operating trajectory of the continuing business.

Shareholder Equity and EPS

The company’s paid-up share capital stands at ₹1,942.6 crore. Other equity excluding revaluation reserve was reported at ₹56,288.2 crore on a standalone basis.

Earnings per share (EPS) for continuing operations were negative, with basic EPS at (₹0.69) for the standalone entity and (₹0.81) on a consolidated basis. When including discontinued operations, the basic EPS stood at (₹0.68) standalone and (₹0.79) consolidated, reflecting the mitigating effect of the profit from discontinued segments on the overall per-share loss.